{
  "schema_version": "pdp_json_v1",
  "peptide": {
    "canonical_name": "Hexarelin",
    "short_name": "Hexarelin",
    "aliases": [
      "HEX"
    ],
    "classification": {
      "category": "investigational_human",
      "needs_prescription": false,
      "notes": "Classification describes what Hexarelin is and the general domain where it appears."
    },
    "status": {
      "category": "investigational_human",
      "jurisdiction": "GLOBAL",
      "last_reviewed": "2026-01-19",
      "human_use_note": "Not FDA-approved. Human use is widely reported in gray-market contexts. Product identity, purity, and dosing consistency are uncertain outside regulated manufacturing."
    },
    "structure": {
      "sequence_oneletter": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "amino_acid_seq": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "molecular_formula": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "molecular_weight": null,
      "structure_image_url": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon."
    },
    "risk": {
      "current_score": 5,
      "severity": "moderate",
      "likelihood": "possible",
      "evidence_grade": "unknown",
      "developmental_risk": true,
      "unknowns_penalty": true,
      "rationale": "Primary risks relate to GH/IGF-1 axis perturbation, metabolic effects (e.g., glucose/insulin signaling), appetite changes, fluid retention, and unknown long-term outcomes in non-medical use. Evidence is limited by heterogeneous study designs and uncertain real-world product quality.",
      "developmental_systems_of_concern": [
        "gh_igf",
        "metabolic",
        "puberty"
      ],
      "risk_score": 5
    },
    "sections": {
      "overview": [
        {
          "claim_type": "overview",
          "title": "What it is",
          "population_group": "general",
          "confidence": "unknown",
          "evidence_grade": "unknown",
          "text": "Hexarelin is a synthetic GHRP-class peptide studied for short-term effects on GH release and downstream endocrine/metabolic signaling. Clinical evidence for meaningful health outcomes is limited; many claims rely on mechanism and small studies rather than robust trials.",
          "evidence_refs": [
            "E1",
            "E2",
            "E3"
          ]
        }
      ],
      "use_cases": [],
      "mechanism": [],
      "human_effects": [],
      "preclinical_effects": [],
      "hypothesized_effects": [],
      "time_dynamics": [],
      "risks": [],
      "contraindications": [],
      "monitoring": [],
      "observed_exposure_ranges": [
        {
          "route": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "unit": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "min": null,
          "max": null,
          "frequency": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "duration": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "population_group": "general",
          "notes": "Descriptive only. Observed in studies; not instructions.",
          "evidence_refs": []
        }
      ],
      "developmental_risk_block": [
        {
          "claim_type": "risk",
          "population_group": "adolescent",
          "confidence": "unknown",
          "evidence_grade": "unknown",
          "text": "Developmental risk is flagged due to limited adolescent data and uncertain long-term effects. Endocrine, growth, neurodevelopmental, and metabolic setpoints may be sensitive to perturbation. This section is descriptive only; uncertainty is explicitly acknowledged.",
          "evidence_refs": []
        }
      ],
      "interaction_summary": [],
      "current_outlook_bullets": [
        "a synthetic GHRP-class peptide studied for short-term effects on GH release and downstream endocrine/metabolic signaling",
        "weight-loss support (commonly discussed)",
        "metabolic health support (anecdotal)",
        "general recovery and resilience interest (anecdotal)",
        "common biohacker curiosity due to community reports",
        "interest in mechanisms suggested by early evidence",
        "used in goal-based stacking discussions (anecdotal)",
        "exploration in wellness communities despite evidence limits"
      ]
    },
    "evidence": [
      {
        "id": "E1",
        "title": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
        "source_type": "pubmed",
        "source_id": "E1",
        "url": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
        "published_date": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
        "evidence_grade": "unknown",
        "notes": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon."
      },
      {
        "id": "E2",
        "title": "Identification of alexamorelin consumption biomarkers using human hepatocyte incubations and high-resolution mass spectrometry.",
        "source_type": "journal_article",
        "source_id": "PMID:40465419",
        "evidence_grade": "human_interventional",
        "year": 2025,
        "url": "https://pubmed.ncbi.nlm.nih.gov/40465419/",
        "notes": "Use to bound claims; does not establish broad clinical benefit."
      },
      {
        "id": "E3",
        "title": "Stimulation of endogenous pulsatile growth hormone secretion by activation of growth hormone secretagogue receptor reduces the fat accumulation and improves the insulin sensitivity in obese mice.",
        "source_type": "review",
        "source_id": "PMID:33368660",
        "evidence_grade": "unknown",
        "year": 2021,
        "url": "https://pubmed.ncbi.nlm.nih.gov/33368660/",
        "notes": "Safety framing; not a protocol guide."
      }
    ],
    "changelog": [
      {
        "date": "2026-01-19",
        "change_type": "initial_entry",
        "summary": "Initial canonical entry for Hexarelin",
        "detail": "Generated from queue ingestion (Phase 6). Requires human-authored, evidence-bounded content.",
        "evidence_refs": []
      },
      {
        "date": "2026-01-19T16:33:35.011290+00:00",
        "change_type": "content_update",
        "summary": "Filled hexarelin core fields and linked conservative evidence refs (no instructions).",
        "detail": "Removed Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon. language from key descriptive fields and ensured overview evidence_refs are present. Evidence entries are intentionally conservative scaffolds and will be finalized with specific PMIDs/years in a batch pass.",
        "evidence_refs": [
          "E1",
          "E2",
          "E3"
        ]
      },
      {
        "date": "2026-01-19T16:47:19.279938+00:00",
        "change_type": "content_update",
        "summary": "Curation update: section structure standardized; content review pending. No protocols or instructions are provided.",
        "detail": "Auto-filled evidence metadata using NCBI E-utilities (query-based). Best-effort year extraction for non-NCBI pages where applicable. No dosing/protocol instructions added.",
        "evidence_refs": []
      }
    ],
    "notes": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
    "meta": {},
    "topics": {
      "primary": [
        "topic_muscle_recovery",
        "topic_hormonal_endocrine"
      ]
    },
    "slug": "hexarelin"
  },
  "canonical_name": "Hexarelin",
  "interactions": {
    "drug_classes": [
      "diabetes-glucose-lowering",
      "antidiabetics-insulin-glp1",
      "endocrine-axis-modulation-context"
    ],
    "supplement_classes": [
      "glucose-lowering-supplements"
    ],
    "peptides": []
  },
  "practical": {
    "bottom_line": "Hexarelin is discussed for growth hormone stimulation and performance/body-composition goals. It is endocrine-active, and non-medical use carries meaningful metabolic and long-term uncertainty.",
    "benefits": [
      "GH-related signaling interest for recovery/body composition themes (variable)",
      "sometimes discussed for sleep quality and training recovery (mixed)",
      "often compared with other GHRPs in performance communities (anecdotal)"
    ],
    "side_effects_common": [
      "increased appetite",
      "water retention or swelling",
      "headache",
      "tingling or numbness sensations"
    ],
    "side_effects_serious": [
      "significant blood sugar worsening symptoms (extreme thirst, confusion, fainting)",
      "severe swelling, shortness of breath, or chest pain",
      "severe allergic reaction symptoms (hives, facial swelling, trouble breathing)"
    ],
    "who_should_be_cautious": [
      "people with diabetes, prediabetes, or metabolic syndrome",
      "people with active cancer or cancer history concerns (growth signaling context)",
      "people with cardiovascular disease or uncontrolled blood pressure",
      "pregnant or breastfeeding individuals",
      "adolescents (endocrine manipulation risk plus inappropriate context)"
    ],
    "schema_version": "practical_block_v1"
  }
}
